Display options
Cite
Remkes WS, Hermanides RS, Kennedy MW, et al. Everolimus-eluting bioresorbable vascular scaffold in daily clinical practice: A single-centre experience. Neth Heart J. 2017;25(11):611-617doi: 10.1007/s12471-017-1038-4.
Remkes, W. S., Hermanides, R. S., Kennedy, M. W., Fabris, E., Kaplan, E., Ottervanger, J. P., van 't Hof, A. W. J., & Kedhi, E. (2017). Everolimus-eluting bioresorbable vascular scaffold in daily clinical practice: A single-centre experience. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 25(11), 611-617. https://doi.org/10.1007/s12471-017-1038-4
Remkes, W S, et al. "Everolimus-eluting bioresorbable vascular scaffold in daily clinical practice: A single-centre experience." Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation vol. 25,11 (2017): 611-617. doi: https://doi.org/10.1007/s12471-017-1038-4
Remkes WS, Hermanides RS, Kennedy MW, Fabris E, Kaplan E, Ottervanger JP, van 't Hof AWJ, Kedhi E. Everolimus-eluting bioresorbable vascular scaffold in daily clinical practice: A single-centre experience. Neth Heart J. 2017 Nov;25(11):611-617. doi: 10.1007/s12471-017-1038-4. PMID: 28913627; PMCID: PMC5653537.
Copy Download .nbib Format: NLM
Share it on

Neth Heart J. 2017 Nov;25(11):611-617. doi: 10.1007/s12471-017-1038-4.

Everolimus-eluting bioresorbable vascular scaffold in daily clinical practice: A single-centre experience.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

W S Remkes, R S Hermanides, M W Kennedy, E Fabris, E Kaplan, J P Ottervanger, A W J van 't Hof, E Kedhi

Affiliations

  1. Isala Hartcentrum, Zwolle, The Netherlands.
  2. Isala Hartcentrum, Zwolle, The Netherlands. [email protected].

PMID: 28913627 PMCID: PMC5653537 DOI: 10.1007/s12471-017-1038-4

Abstract

BACKGROUND: Recent evidence has raised concerns regarding the safety of the everolimus-eluting bioresorbable vascular scaffold (E-BVS) (Absorb, Abbott Vascular, Santa Clara, CA, USA). Following these data, the use of this device has diminished in the Netherlands; however, daily practice data are limited. Therefore we studied the incidence of safety and efficacy outcomes with this device in daily clinical practice in a single large tertiary centre in the Netherlands.

METHODS: All E‑BVS treated patients were included in this analysis. The primary endpoint was target lesion failure (TLF), a composite of cardiac death, target vessel non-fatal myocardial infarction (TV-MI) and clinically-driven target lesion revascularisation (TLR). The secondary endpoint was the incidence of definite scaffold thrombosis.

RESULTS: Between October 2013 and January 2017, 105 patients were treated with 147 E‑BVS. This population contained 42 (40%) patients with diabetes mellitus and 43 (40.9%) undergoing treatment for acute coronary syndrome, and thus represents a high-risk patient cohort. Mean follow-up was 19.8 months. Intravascular imaging guidance during scaffold implantation was used in 64/105 (43.5%) patients. The primary endpoint (TLF) occurred in 3 (2.9%) patients. All-cause mortality and cardiac mortality occurred in 2 (2%) and 0 (0%) patients respectively. TV-MI occurred in 2 patients (1.9%): both were periprocedural and not related to the BVS implantation. TLR occurred in 1 patient (1.0%) during follow-up. No definite scaffold thrombosis occurred during follow-up.

CONCLUSION: This single-centre study examining the real-world experience of E‑BVS implantation in a high-risk population shows excellent procedural safety and long-term clinical outcomes.

Keywords: Bioresorbable scaffold; Coronary artery disease; Percutaneous coronary intervention; Scaffold thrombosis

References

  1. EuroIntervention. 2009 Dec 15;5 Suppl F:F15-22 - PubMed
  2. JACC Cardiovasc Interv. 2015 Jan;8(1 Pt B):189-197 - PubMed
  3. J Am Coll Cardiol. 2012 Oct 16;60(16):1581-98 - PubMed
  4. J Am Coll Cardiol. 2015 Mar 3;65(8):791-801 - PubMed
  5. EuroIntervention. 2017 Feb 20;12 (14 ):1730-1737 - PubMed
  6. Circ Cardiovasc Interv. 2015 May;8(5):null - PubMed
  7. Catheter Cardiovasc Interv. 2016 Apr;87(5):839-46 - PubMed
  8. Eur Heart J. 2015 Dec 14;36(47):3332-42 - PubMed
  9. N Engl J Med. 2015 Nov 12;373(20):1905-15 - PubMed
  10. EuroIntervention. 2017 Feb 20;12 (14 ):1747-1756 - PubMed
  11. EuroIntervention. 2015 May;11(1):45-52 - PubMed
  12. Int J Cardiol. 2015 Dec 15;201:129-36 - PubMed
  13. Eur Heart J. 2015 Feb 7;36(6):393 - PubMed
  14. JACC Cardiovasc Interv. 2016 Jan 11;9(1):12-24 - PubMed
  15. J Am Coll Cardiol. 2016 Mar 1;67(8):921-31 - PubMed
  16. Circ Cardiovasc Interv. 2014 Apr;7(2):180-9 - PubMed
  17. N Engl J Med. 2017 Jun 15;376(24):2319-2328 - PubMed
  18. Lancet. 2015 Jan 3;385(9962):43-54 - PubMed
  19. J Am Coll Cardiol. 2015 Dec 1;66(21):2298-2309 - PubMed
  20. Catheter Cardiovasc Interv. 2015 Nov 15;86(6):984-91 - PubMed
  21. EuroIntervention. 2014 Aug;10(4):449-57 - PubMed
  22. Lancet. 2016 Nov 19;388(10059):2479-2491 - PubMed
  23. Catheter Cardiovasc Interv. 2015 Jan 1;85(1):E10-5 - PubMed
  24. EuroIntervention. 2015 May;11(1):60-7 - PubMed
  25. Circulation. 2007 May 1;115(17):2344-51 - PubMed
  26. EuroIntervention. 2016 Oct 20;12 (9):1090-1101 - PubMed

Publication Types